Trial · NCT00957671

Anterior Pituitary Hormone Replacement in Traumatic Brain Injury

NCT00957671, Phase 4, Completed, The University of Texas Medical Branch, Galveston; results first posted 2018-05-15

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Anterior Pituitary Hormone Replacement in Traumatic Brain Injury. Trials, record NCT00957671. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00957671

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Anterior Pituitary Hormone Replacement in Traumatic Brain Injury
NCT number: NCT00957671
Status: Completed
Phases: Phase 4
Enrollment: 15 participants, actual
Lead sponsor: The University of Texas Medical Branch, Galveston
Conditions: Growth Hormone Deficiency, Traumatic Brain Injury
Interventions: Recombinant human growth hormone
First posted: 2009-08-12
Last updated: 2018-06-29
Results first posted: 2018-05-15

Source ClinicalTrials.gov

Registered outcomes54

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Maximum Oxygen Uptake at Baseline.	baseline	Maximum Oxygen Uptake was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.
Primary	Maximum Oxygen Uptake After One Year of Human Growth Hormone Replacement Therapy.	one year	Maximum Oxygen Uptake was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.
Primary	Minute Ventilation at Baseline.	baseline	Minute ventilation was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.
Primary	Minute Ventilation After One Year of Human Growth Hormone Replacement Therapy.	one year	Minute ventilation was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.
Primary	Respiratory Exchange Ratio at Baseline.	baseline	Respiratory exchange ratio was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.
Primary	Respiratory Exchange Ratio After One Year of Human Growth Hormone Replacement Therapy.	one year	Respiratory exchange ratio was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.
Primary	Oxygen Pulse at Baseline.	baseline	Oxygen Pulse was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart. Oxygen pulse is calculated by dividing VO2 consumed (mL/min) by heart rate (beats/min) yielding mL/beat. This provides an estimate of cardiac stroke volume.
Primary	Oxygen Pulse After One Year of Human Growth Hormone Replacement Therapy.	one year	Oxygen Pulse was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart. Oxygen pulse is calculated by dividing VO2 consumed (mL/min) by heart rate (beats/min) yielding mL/beat. This provides an estimate of cardiac stroke volume.
Secondary	Neuropsychological Function as Measured by California Verbal Learning Test-II With Total Recall at Baseline.	baseline	The California Verbal Learning Test II (CVLT-II) is a comprehensive assessment of verbal learning and memory. Subjects are read a list of 16 words. Total recall is a sum of all word list items correctly recalled immediately on learning trials 1 through 5. Data is reported as raw scores. Score range is 0 (lowest) to 80 (highest). A higher score indicates a better outcome.
Secondary	Neuropsychological Function as Measured by California Verbal Learning Test-II With Total Recall After 1 Year of Human Growth Hormone Replacement Therapy.	One year	The California Verbal Learning Test II (CVLT-II) is a comprehensive assessment of verbal learning and memory. Subjects are read a list of 16 words. Total recall is a sum of all word list items correctly recalled immediately on learning trials 1 through 5. Data is reported as raw scores. Score range is 0 (lowest) to 80 (highest). A higher score indicates a better outcome.

1 to 10 of 54Source ClinicalTrials.gov

See all 54 registered outcomes

Outcomes54

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Maximum Oxygen Uptake at Baseline.	baseline	mL/kg/min	MEAN
PRIMARY	Maximum Oxygen Uptake After One Year of Human Growth Hormone Replacement Therapy.	one year	mL/kg/min	MEAN
PRIMARY	Minute Ventilation at Baseline.	baseline	L/minute	MEAN
PRIMARY	Minute Ventilation After One Year of Human Growth Hormone Replacement Therapy.	one year	L/minute	MEAN
PRIMARY	Respiratory Exchange Ratio at Baseline.	baseline	ratio of CO2/O2	MEAN
PRIMARY	Respiratory Exchange Ratio After One Year of Human Growth Hormone Replacement Therapy.	one year	ratio of CO2/O2	MEAN
PRIMARY	Oxygen Pulse at Baseline.	baseline	mL/beat	MEAN
PRIMARY	Oxygen Pulse After One Year of Human Growth Hormone Replacement Therapy.	one year	mL/beat	MEAN
SECONDARY	Neuropsychological Function as Measured by California Verbal Learning Test-II With Total Recall at Baseline.	baseline	scores on a scale	MEAN
SECONDARY	Neuropsychological Function as Measured by California Verbal Learning Test-II With Total Recall After 1 Year of Human Growth Hormone Replacement Therapy.	One year	scores on a scale	MEAN

1 to 10 of 54Source ClinicalTrials.gov

See all 54 outcomes

Results by group54

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Maximum Oxygen Uptake at Baseline.	Human Growth Hormone	29.0	Standard Deviation 7.2	mL/kg/min
Maximum Oxygen Uptake After One Year of Human Growth Hormone Replacement Therapy.	Human Growth Hormone	32.1	Standard Deviation 7.4	mL/kg/min
Minute Ventilation at Baseline.	Human Growth Hormone	90.4	Standard Deviation 24.2	L/minute
Minute Ventilation After One Year of Human Growth Hormone Replacement Therapy.	Human Growth Hormone	102.4	Standard Deviation 23.1	L/minute
Respiratory Exchange Ratio at Baseline.	Human Growth Hormone	1.27	Standard Deviation 0.12	ratio of CO2/O2
Respiratory Exchange Ratio After One Year of Human Growth Hormone Replacement Therapy.	Human Growth Hormone	1.27	Standard Deviation 0.10	ratio of CO2/O2
Oxygen Pulse at Baseline.	Human Growth Hormone	15.2	Standard Deviation 4.1	mL/beat
Oxygen Pulse After One Year of Human Growth Hormone Replacement Therapy.	Human Growth Hormone	16.4	Standard Deviation 4.2	mL/beat
Neuropsychological Function as Measured by California Verbal Learning Test-II With Total Recall at Baseline.	Human Growth Hormone	45.7	Standard Deviation 10.8	scores on a scale
Neuropsychological Function as Measured by California Verbal Learning Test-II With Total Recall After 1 Year of Human Growth Hormone Replacement Therapy.	Human Growth Hormone	51.0	Standard Deviation 9.4	scores on a scale

1 to 10 of 54Source ClinicalTrials.gov

See all 54 results by group

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Human Growth Hormone	15
Overall Study	COMPLETED	Human Growth Hormone	15
Overall Study	NOT COMPLETED	Human Growth Hormone	0

Source ClinicalTrials.gov

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals3

The totals the trial posted for each group.

Total	Group	At risk
Total, all-cause mortality	Human Growth Hormone	15
Total, other adverse events	Human Growth Hormone	15
Total, serious adverse events	Human Growth Hormone	15

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests4

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

Test	Named as	Source
Digit Span Test	Secondary outcome	ConductCognition
Symbol Scan Task	Secondary outcome	ConductCognition
Verbal Fluency	Secondary outcome	ConductCognition
Verbal Learning	Secondary outcome	ConductCognition

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00957671

GET https://conductscience.org/api/trials/v1/NCT00957671/registered?page=2

API reference For AI assistants